CoChat

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Open access
Das, Anirban, Sudhaman, Sumedha, Morgenstern, Daniel, Coblentz, Ailish, Chung, Jiil, Stone, Simone C., Alsafwani, Noor, Liu, Zhihui Amy, Karsaneh, Ola Abu Al, Soleimani, Shirin, Ladany, Hagay, Chen, David, Zatzman, Matthew, Cabric, Vanja, Nobre, Liana, Bianchi, Vanessa, Edwards, Melissa, Sambira Nahum, Lauren C,, Ercan, Ayse B., Nabbi, Arash, Constantini, Shlomi, Dvir, Rina, Yalon-Oren, Michal, Campino, Gadi Abebe, Caspi, Shani, Larouche, Valerie, Reddy, Alyssa, Osborn, Michael, Mason, Gary, Lindhorst, Scott, Bronsema, Annika, Magimairajan, Vanan, Opocher, Enrico, De Mola, Rebecca Loret, Sabel, Magnus, Frojd, Charlotta, Sumerauer, David, Samuel, David, Cole, Kristina, Chiaravalli, Stefano, Massimino, Maura, Tomboc, Patrick, Ziegler, David S., George, Ben, Van Damme, An, Hijiya, Nobuko, Gass, David, McGee, Rose B., Mordechai, Oz, Bowers, Daniel C., Laetsch, Theodore W., Lossos, Alexander, Blumenthal, Deborah T., Sarosiek, Tomasz, Yen, Lee Yi, Knipstein, Jeffrey, Bendel, Anne, Hoffman, Lindsey M., Luna-Fineman, Sandra, Zimmermann, Stefanie, Scheers, Isabelle, Nichols, Kim E., Zapotocky, Michal, Hansford, Jordan R., Maris, John M., Dirks, Peter, Taylor, Michael D., Kulkarni, Abhaya V., Shroff, Manohar, Tsang, Derek S., Villani, Anita, Xu, Wei, Aronson, Melyssa, Durno, Carol, Shlien, Adam, Malkin, David, Getz, Gad, Maruvka, Yosef E., Ohashi, Pamela S., Hawkins, Cynthia, Pugh, Trevor J., Bouffet, Eric, Tabori, Uri · 2022 · Nature Medicine
Cited by 155

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Cancers arising from germline DNA mismatch repair deficiency or polymerase proofreading deficiency (MMRD and PPD) in children harbour the highest mutational and microsatellite insertion–deletion (MS-indel) burden in humans. MMRD and PPD cancers are commonly lethal due to the inherent resistance to chemo-irradiation. Although immune checkpoint inhibitors (ICIs) have failed to benefit children in previous studies, we hypothesized that hypermutation caused by MMRD and PPD will improve outcomes following ICI treatment in these patients. Using an international consortium registry study, we report on the ICI treatment of 45 progressive or recurrent tumors from 38 patients. Durable objective responses were observed in most patients, culminating in a 3 year survival of 41.4%. High mutation burden predicted response for ultra-hypermutant cancers (>100 mutations per Mb) enriched for combined MMRD + PPD, while MS-indels predicted response in MMRD tumors with lower mutation burden (10–100 mutations per Mb). Furthermore, both mechanisms were associated with increased immune infiltration even in ‘immunologically cold’ tumors such as gliomas, contributing to the favorable response. Pseudo-progression (flare) was common and was associated with immune activation in the tumor microenvironment and systemically. Furthermore, patients with flare who continued ICI treatment achieved durable responses. This study demonstrates improved survival for patients with tumors not previously known to respond to ICI treatment, including central nervous system and synchronous cancers, and identifies the dual roles of mutation burden and MS-indels in predicting sustained response to immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01581-6

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 155

Metadata

Authors
Das, A., Sudhaman, S., Morgenstern, D., Coblentz, A., Chung, J., Stone, S. C., Alsafwani, N., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., Ladany, H., Chen, D., Zatzman, M., Cabric, V., Nobre, L., Bianchi, V., Edwards, M., Sambira Nahum, L. C., Ercan, A. B., Nabbi, A., Constantini, S., Dvir, R., Yalon-Oren, M., Campino, G. A., Caspi, S., Larouche, V., Reddy, A., Osborn, M., Mason, G., Lindhorst, S., Bronsema, A., Magimairajan, V., Opocher, E., De Mola, R. L., Sabel, M., Frojd, C., Sumerauer, D., Samuel, D., Cole, K., Chiaravalli, S., Massimino, M., Tomboc, P., Ziegler, D. S., George, B., Van Damme, A., Hijiya, N., Gass, D., McGee, R. B., Mordechai, O., Bowers, D. C., Laetsch, T. W., Lossos, A., Blumenthal, D. T., Sarosiek, T., Yen, L. Y., Knipstein, J., Bendel, A., Hoffman, L. M., Luna-Fineman, S., Zimmermann, S., Scheers, I., Nichols, K. E., Zapotocky, M., Hansford, J. R., Maris, J. M., Dirks, P., Taylor, M. D., Kulkarni, A. V., Shroff, M., Tsang, D. S., Villani, A., Xu, W., Aronson, M., Durno, C., Shlien, A., Malkin, D., Getz, G., Maruvka, Y. E., Ohashi, P. S., Hawkins, C., Pugh, T. J., Bouffet, E., & Tabori, U.
Venue
Nature Medicine
Published
2022-01
Volume
28
Issue
1
Pages
125-135
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4205106080
Cited by
155
References
27
FWCI
11.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. https://app.cochat.ai/papers/10.1038/s41591-021-01581-6
The paper
Das, A., Sudhaman, S., Morgenstern, D., Coblentz, A., Chung, J., Stone, S. C., Alsafwani, N., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., Ladany, H., Chen, D., Zatzman, M., Cabric, V., Nobre, L., Bianchi, V., Edwards, M., Sambira Nahum, L. C., Ercan, A. B., . . . Tabori, U. (2022). Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine. https://doi.org/10.1038/s41591-021-01581-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.